FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149883352> ?p ?o ?g. }

• W2149883352 endingPage "S160" @default.
• W2149883352 startingPage "S147" @default.
• W2149883352 abstract "This review of the safety of the co-administration regimens to be used in programmes to eliminate lymphatic filariasis (albendazole + ivermectin or albendazole + diethylcarbamazine [DEC]) is based on 17 studies conducted in Sri Lanka, India, Haiti, Ghana, Tanzania, Kenya, Ecuador, the Philippines, Gabon, Papua New Guinea, and Bangladesh. The total data set comprises 90,635 subject exposures and includes individuals of all ages and both genders. Results are presented for hospital-based studies, laboratory studies, active surveillance of microfilaria-positive and microfilaria-negative individuals, and passive monitoring in both community-based studies and mass treatment programmes of individuals treated with albendazole (n = 1538), ivermectin (9822), DEC (576), albendazole + ivermectin (7470), albendazole + DEC (69,020), or placebo (1144). The most rigorous monitoring, which includes haematological and biochemical laboratory parameters pre- and post-treatment, provides no evidence that consistent changes are induced by any treatment; the majority of abnormalities appear to be sporadic, and the addition of albendazole to either ivermectin or DEC does not increase the frequency of abnormalities. Both DEC and ivermectin show, as expected, an adverse event profile compatible with the destruction of microfilariae. The addition of albendazole to either single-drug treatment regimen does not appear to increase the frequency or intensity of events seen with these microfilaricidal drugs when used alone. Direct observations indicated that the level of adverse events, both frequency and intensity, was correlated with the level of microfilaraemia. In non microfilaraemic individuals, who form 80-90% of the 'at risk' populations to be treated in most national public health programmes to eliminate lymphatic filariasis (LF), the event profile with the compounds alone or in combination does not differ significantly from that of placebo. Data on the use of ivermectin + albendazole in areas either of double infection (onchocerciasis and LF), or of loiais (with or without concurrent LF) are still inadequate and further studies are needed. Additional data are also recommended for populations infected with Brugia malayi, since most data thus far derive from populations infected with Wuchereria bancrofti." @default.
• W2149883352 created "2016-06-24" @default.
• W2149883352 creator A5006117124 @default.
• W2149883352 creator A5009210238 @default.
• W2149883352 creator A5015649778 @default.
• W2149883352 creator A5019115942 @default.
• W2149883352 creator A5038436721 @default.
• W2149883352 creator A5041307705 @default.
• W2149883352 creator A5044873135 @default.
• W2149883352 creator A5047246603 @default.
• W2149883352 creator A5050938934 @default.
• W2149883352 creator A5051874856 @default.
• W2149883352 creator A5052325013 @default.
• W2149883352 creator A5055160749 @default.
• W2149883352 creator A5062353866 @default.
• W2149883352 creator A5062740618 @default.
• W2149883352 creator A5068349933 @default.
• W2149883352 creator A5069199746 @default.
• W2149883352 creator A5070835751 @default.
• W2149883352 creator A5071496730 @default.
• W2149883352 creator A5073315196 @default.
• W2149883352 creator A5074809035 @default.
• W2149883352 creator A5091627380 @default.
• W2149883352 creator A5091711917 @default.
• W2149883352 date "2000-10-01" @default.
• W2149883352 modified "2023-10-01" @default.
• W2149883352 title "An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis" @default.
• W2149883352 cites W1508261324 @default.
• W2149883352 cites W1991279333 @default.
• W2149883352 cites W2003861955 @default.
• W2149883352 cites W2110486035 @default.
• W2149883352 cites W2143295469 @default.
• W2149883352 cites W3112728020 @default.
• W2149883352 doi "https://doi.org/10.1017/s0031182000007423" @default.
• W2149883352 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11386686" @default.
• W2149883352 hasPublicationYear "2000" @default.
• W2149883352 type Work @default.
• W2149883352 sameAs 2149883352 @default.
• W2149883352 citedByCount "92" @default.
• W2149883352 countsByYear W21498833522012 @default.
• W2149883352 countsByYear W21498833522013 @default.
• W2149883352 countsByYear W21498833522014 @default.
• W2149883352 countsByYear W21498833522015 @default.
• W2149883352 countsByYear W21498833522016 @default.
• W2149883352 countsByYear W21498833522017 @default.
• W2149883352 countsByYear W21498833522018 @default.
• W2149883352 countsByYear W21498833522019 @default.
• W2149883352 countsByYear W21498833522020 @default.
• W2149883352 countsByYear W21498833522021 @default.
• W2149883352 countsByYear W21498833522023 @default.
• W2149883352 crossrefType "journal-article" @default.
• W2149883352 hasAuthorship W2149883352A5006117124 @default.
• W2149883352 hasAuthorship W2149883352A5009210238 @default.
• W2149883352 hasAuthorship W2149883352A5015649778 @default.
• W2149883352 hasAuthorship W2149883352A5019115942 @default.
• W2149883352 hasAuthorship W2149883352A5038436721 @default.
• W2149883352 hasAuthorship W2149883352A5041307705 @default.
• W2149883352 hasAuthorship W2149883352A5044873135 @default.
• W2149883352 hasAuthorship W2149883352A5047246603 @default.
• W2149883352 hasAuthorship W2149883352A5050938934 @default.
• W2149883352 hasAuthorship W2149883352A5051874856 @default.
• W2149883352 hasAuthorship W2149883352A5052325013 @default.
• W2149883352 hasAuthorship W2149883352A5055160749 @default.
• W2149883352 hasAuthorship W2149883352A5062353866 @default.
• W2149883352 hasAuthorship W2149883352A5062740618 @default.
• W2149883352 hasAuthorship W2149883352A5068349933 @default.
• W2149883352 hasAuthorship W2149883352A5069199746 @default.
• W2149883352 hasAuthorship W2149883352A5070835751 @default.
• W2149883352 hasAuthorship W2149883352A5071496730 @default.
• W2149883352 hasAuthorship W2149883352A5073315196 @default.
• W2149883352 hasAuthorship W2149883352A5074809035 @default.
• W2149883352 hasAuthorship W2149883352A5091627380 @default.
• W2149883352 hasAuthorship W2149883352A5091711917 @default.
• W2149883352 hasConcept C126322002 @default.
• W2149883352 hasConcept C141071460 @default.
• W2149883352 hasConcept C165901193 @default.
• W2149883352 hasConcept C197934379 @default.
• W2149883352 hasConcept C203014093 @default.
• W2149883352 hasConcept C2776158911 @default.
• W2149883352 hasConcept C2776908094 @default.
• W2149883352 hasConcept C2777065887 @default.
• W2149883352 hasConcept C2777411658 @default.
• W2149883352 hasConcept C2777499811 @default.
• W2149883352 hasConcept C2777629521 @default.
• W2149883352 hasConcept C2778672586 @default.
• W2149883352 hasConcept C2779359454 @default.
• W2149883352 hasConcept C2780133432 @default.
• W2149883352 hasConcept C2780727990 @default.
• W2149883352 hasConcept C2781413609 @default.
• W2149883352 hasConcept C2908647359 @default.
• W2149883352 hasConcept C2911037157 @default.
• W2149883352 hasConcept C42972112 @default.
• W2149883352 hasConcept C71924100 @default.
• W2149883352 hasConcept C99454951 @default.
• W2149883352 hasConceptScore W2149883352C126322002 @default.
• W2149883352 hasConceptScore W2149883352C141071460 @default.
• W2149883352 hasConceptScore W2149883352C165901193 @default.
• W2149883352 hasConceptScore W2149883352C197934379 @default.

• next